Screener
Viridian Therapeutics, Inc. VRDN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s retained earnings?
- Viridian Therapeutics, Inc. (VRDN) reported retained earnings of -$1.57B in Q2 2026.
- How has Viridian Therapeutics, Inc.'s retained earnings changed year-over-year?
- Viridian Therapeutics, Inc.'s retained earnings decreased by 32.7% year-over-year, from -$1.18B to -$1.57B.
- What is the long-term trend for Viridian Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s retained earnings has grown at a 36.8% compound annual growth rate (CAGR), from -$278.89M to -$1.34B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Viridian Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude